Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Argatroban
Drug ID BADD_D00161
Description Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Indications and Usage Argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
Marketing Status Prescription; Discontinued
ATC Code B01AE03
DrugBank ID DB00278
KEGG ID C04931
MeSH ID C031942
PubChem ID 92722
NDC Product Code 0078-0930; 68083-141; 0143-9288; 65145-126; 16729-430; 65219-429; 0409-1140; 55150-241; 70121-1037; 63323-526; 0143-9674; 25021-414; 0143-9377; 42023-182; 67457-212; 55486-1582; 76339-118; 45562-1124; 70333-1191; 0143-9559; 62227-015
Synonyms argatroban | MPQA | (2R,4R)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid monohydrate | MMTQAP | argatroban monohydrate | argatroban hydrate | Acova | (21R)-argatroban anhydrous | (2R,4R)-1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3R)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | (21S)-argatroban anhydrous | (2R,4R)-1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3S)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | (21S)-argatroban | (21R)-argatroban | MD 805 | MD805 | MD-805 | Novastan | argatroban anhydrous | (2R,4R)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | MCI 9038 | MCI-9038
Chemical Information
Molecular Formula C23H36N6O5S
CAS Registry Number 74863-84-6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Activated partial thromboplastin time abnormal13.01.02.0190.000371%Not Available
Activated partial thromboplastin time prolonged13.01.02.0010.001855%
Acute hepatic failure09.01.03.0010.000097%Not Available
Alanine aminotransferase increased13.03.01.0030.000371%
Angina pectoris02.02.02.002;
Angina unstable24.04.04.004; Available
Aortic stenosis24.04.01.001--Not Available
Aortic thrombosis24.01.09.0010.000556%Not Available
Aortic valve stenosis02.07.03.004--Not Available
Arterial thrombosis24.01.01.002--Not Available
Aspartate aminotransferase increased13.03.01.0060.000371%
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Cardiac arrest02.03.04.0010.000145%
Cardiac failure02.05.01.0010.000145%
Cardiogenic shock24.06.02.006; Available
Cerebral haemorrhage24.07.04.001; Available
Cerebral infarction17.08.01.004; Available
Cerebrovascular accident24.03.05.001;
Cerebrovascular disorder17.08.02.002; Available
Chest pain22.02.08.003;; Available
Coagulation time prolonged13.01.02.0060.000742%Not Available
Coagulopathy01.01.02.0010.000742%Not Available
Confusional state19.13.01.001;
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages